Immunotherapy Clinical Trials


Megan Othus April 27, 2017

Idea: Use body's immune system to recognize and kill cancer cells

Not a new idea, but there are some high-profile newer drugs in this class


Examples of immunotherapies in oncology: Cancer vaccines

Example: BCG in bladder cancer




Examples of immunotherapies in oncology: Cytokines

Example: IL-2 in melanoma and renal carcinoma; Interferon in melanoma and some hematologic malignancies




Examples of immunotherapies in oncology: Allogeneic transplant

Example: Leukemias




Examples of immunotherapies in oncology: Oncolytic viruses

Example: T-vec in melanoma



Examples of immunotherapies in oncology: Monoclonal antibodies


Examples: trastuzumab in breast cancer (HER2), alemtuzumab in CLL (CD52), rituximab in non-Hodgkin's lymphoma (CD20), cetuximab (colorectal carcinoma), blinatumomab for ALL, CTLA-4 and PDL1 therapies for melanoma and other cancers



7/20


Examples of immunotherapies in oncology: CAR T-cell therapy

Example: leukemia and lymphoma




Examples of immunotherapies in oncology: Checkpoint inhibitors

Example: CTLA-4 and PDL1 drugs for a variety of cancers






- Adjuvant therapy for advanced melanoma
- Control arm: Patient/physician choice of High-dose Interferon (cytokine therapy) or Ipilimumab (CTLA-4 therapy)
- Experimental arm: Pembrolizumab (PDL1 therapy)
- FDA registration trial



S1404 accrual

S1404 accrual implications



S1404 accrual

First interim/RFS analysis was planned for Fall 2019, now is expected Fall 2018.

If pembrolizumab is strongly positive at the first interim/RFS analysis:


- Merck will take the trial results to the FDA and European Health Authorities
- SWOG will have to provide all that data to Merck
- SWOG sites can and will be audited by the FDA

Because S1404 is an FDA registration trial, we need:


- More data than usual
 - especially detailed AE data
- No missing data
 - even if a test wasn't done, we need to document why it wasn't done and so why it is missing
- All of the scans done
 - scan images have to uploaded through Triad into Rave
- QOL data
 - Some European countries require QOL data

Because S1404 is a FDA registration trial, we need PDL1 status on all patients randomized.


Specimen Submission Tally	N (%)
One submission	805 (87%)
Two submissions	115 (12%)
Three submissions	7 (1%)
Four submissions	2 (<1%)




Marker stratification – ignoring PDL1



Marker stratification – PDL1 positive



Marker stratification - PDL1 negative



Questions?